COVID-19 vaccine: Serum Institute of India to begin Phase 2 trial of Oxford-Astrazeneca candidate today
The DCGI on 3 August had given nod to the Pune Serum Institute of India for conducting phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate
The decision was taken after the drug controller found the companies' response to a 17 July show-cause notice asking them to explain why their licences should not be suspended unsatisfactory
India has allowed adults and children who have been hospitalised with severe COVID-19 symptoms to be treated with Remdesivir
The administration of this drug will be given to patients who show signs of a sever COVID-19 infection for a period of five days as well.
Indian drug makers will eventually have to invest in infrastructure and commit to high quality standards to ensure they get market access to America.
The report by parliament's health committee painted a chaotic picture of the Central Drugs Standard Control Organisation (CDSCO), which oversees the licensing, marketing and trials of drugs in India.